Full-Time

Associate Director

Regulatory Affairs

Updated on 9/9/2026

Pulmovant

Pulmovant

11-50 employees

Clinical-stage biotech developing inhaled sGC activator

No salary listed

Remote in USA

Remote

Travel up to 10% may be required to meet with vendors and regulators.

Bachelor's, Master's, PharmD, PhD

Category
Biology & Biotech (1)
Required Skills
SharePoint
Veeva
Financial analysis
Word/Pages/Docs
Excel/Numbers/Sheets

Get referred to Pulmovant

See people who can refer or advise you

Requirements
  • Education equivalent to a Bachelor of Science degree in a scientific field plus 7 years of regulatory affairs experience, or education equivalent to a Master of Science degree in a scientific field plus 5 years of regulatory affairs experience, or education equivalent to a Doctor of Philosophy or Doctor of Pharmacy degree in a scientific field plus 3 years of regulatory affairs experience.
  • Experience working with the United States Food and Drug Administration is essential.
  • Experience with global clinical trials using a contract research organization.
  • Excellent verbal, written, and interpersonal communication skills, with the ability to interact with internal teams and partners across all organizational levels.
  • Ability to present information effectively and respond to questions from all organizational levels.
  • Ability to multitask in a fast-paced environment and work well under pressure while meeting time-sensitive deadlines.
  • Ability to collaborate with colleagues across functional areas in a science-driven environment.
  • Ability to work across locations and time zones.
  • Proficiency using Microsoft Word, Excel, PowerPoint, Adobe, and SharePoint or similar applications and systems.
  • Strong financial business acumen and analytical skills, including the ability to develop and manage expenditures in accordance with a budget.
  • Regulatory Affairs Certification is a plus for drugs and/or devices.
Responsibilities
  • Represent Regulatory Affairs in assigned project meetings and provide regulatory guidance to cross-functional project teams.
  • Provide regulatory guidance to colleagues preparing regulatory documents.
  • Serve as the regulatory affairs contact for external parties, including contract research organizations and advisors, involved in global clinical trials.
  • Contribute to global regulatory strategy for clinical trial and registration submissions in accordance with applicable regulations and guidelines.
  • Plan, prepare, author, and review documentation and submissions, including Investigational New Drug applications, Clinical Trial Applications, Biologics License Applications, New Drug Applications, and Marketing Authorization Applications.
  • Liaise with global health authorities as agreed with the Director of Regulatory Affairs and Head of Regulatory Affairs.
  • Contribute to competitive regulatory strategies that expedite development, maximize the probability of success, and mitigate risks.
  • Communicate project updates and risks to senior regulatory affairs management and organizational stakeholders.
  • Track regulatory deliverables and coordinate with internal and external staff to ensure timely submissions.
  • Coordinate and prepare responses to requests for information from health authorities.
  • Prepare meeting requests and briefing documents, and coordinate and prepare teams for meetings with health authorities.
  • Contribute to internal regulatory affairs policies and procedures aligned with good practice requirements, guidance documents, and corporate objectives.
  • Monitor, analyze, and disseminate intelligence on regulatory matters related to assigned responsibilities.
Desired Qualifications
  • Additional experience with European Union, Japan, and other global health authorities.
  • Experience interacting with the United States Food and Drug Administration Division of Cardiology and Nephrology.
  • Experience with pulmonary hypertension and other pulmonary diseases.
  • Experience with drug-device combination products.
  • Experience using Veeva or similar applications and systems.

Pulmovant focuses on developing mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator, as a therapy for pulmonary diseases, especially pulmonary hypertension associated with interstitial lung disease (PH-ILD). It advances mosliciguat through clinical trials with a dry powder inhaler designed for targeted delivery to the lungs to cause pulmonary vasodilation while aiming to limit systemic exposure. The company differentiates itself by pursuing a first-in-class inhaled sGC activator, leveraging Roivant’s biotech ecosystem, and seeking regulatory advantages such as orphan drug designation in Japan, to address a patient group of about 200,000 in the U.S. and Europe who have few treatment options. Pulmovant is moving mosliciguat through Phase 2 programs (PHocus and PHactor) with topline Phase 2 results anticipated in late 2026, and aims to progress toward regulatory approval and broader access for PH-ILD patients.

Company Size

11-50

Company Stage

N/A

Total Funding

N/A

Headquarters

Waltham, Massachusetts

Founded

N/A

Get referred to Pulmovant

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PHocus finished enrollment in February 2026, showing strong site execution and patient demand.
  • July 2026 Phase 1 data showed target engagement, low systemic exposure, and no serious adverse events.
  • Japan granted orphan designation in September 2025, improving regulatory momentum and partnerability.

What critics are saying

  • PHocus data arrives in second-half 2026; a miss kills the only clinical value driver.
  • Inhaled treprostinil remains the only proven PH-ILD therapy, squeezing adoption and pricing.
  • Bayer retains milestones and royalties; weak efficacy leaves Pulmovant stranded as a one-asset Vant.

What makes Pulmovant unique

  • Mosliciguat is a first-in-class, once-daily inhaled sGC activator for PH-ILD.
  • Pulmovant targets lung-selective vasodilation, seeking efficacy with less systemic hypotension than oral vasodilators.
  • Roivant owns 97% of Pulmovant, giving disciplined capital and shared operating infrastructure.

Help us improve and share your feedback! Did you find this helpful?